6.10 Research Study after donation OR Donor Blood Samples after Donation ..........19
6.11 Cryopreservation of Stem Cell Products ....................................................19
6.12 Partial Cryopreservation of Excess Cells of Stem Cell Products .......................20
6.13 Cryopreservation of MNCs ........................................................................20
6.14 Unavailability of a Donor for One Product Type ...........................................21
6.15 Additional Testing Requests by the Transplant Center ....................................21
6.16 Maximum Amount of Blood to be drawn at Physical Examination (Pre-Collection Samples) ..........................................................22
6.17 Transplant Center Acceptance of Formally Ineligible Donors ........................22
6.18 Donor Reservation after Donation .................................................................22
7 Requests for Adult Donor Cryopreserved Units (ADCU) ....................................23
8 Transport .............................................................................................................23
  8.1 Transport Arrangements by International Registries and Transplant Centers ......24
  8.2 Transport Arrangements to be made by DKMS ..............................................24
9 Donor Follow-Up ...............................................................................................24
  9.1 Post-Donation Follow-Up ..............................................................................24
  9.2 Adverse Events and Reactions Reporting (SEAR/SPEAR) .............................25
10 Donor-Patient Contacts ....................................................................................25
  10.1 Anonymity Criteria for DKMS Donors and / or Patients of DKMS Registry ....25
  10.2 Patient Follow-Up Information ..................................................................26
  10.3 Release of Personal Information between Donor and Recipient .....................26
11 Finance ..............................................................................................................27
  11.1 Fee Schedule .................................................................................................27
12 Applicability for access via ZKRD, NMDP, Anthony Nolan and Poltransplant........27
1 Preamble

This operational user guide is enforced at DKMS Registry gGmbH and the DKMS donor centers, DKMS Donor Center gGmbH in Germany (DKMS DE), Fundacja DKMS in Poland (DKMS PL), DKMS Foundation in the United Kingdom (DKMS UK), Fundación de Beneficencia Pública DKMS in Chile (DKMS CL), DKMS BMST Foundation India (DKMS BMST IN), DKMS Foundation NPC in South Africa (DKMS Africa) and DKMS in the United States of America (DKMS USA) - together referred to as DKMS. It describes the rules and procedures in place that have to be followed by transplant centers, search units and international registries using services of DKMS. It further includes guidelines around processes of DKMS Stem Cell Bank (DKMS SCB).

DKMS Registry is WMDA qualified since 2021 and is moving towards full standard certification in 2024. DKMS in Germany is WMDA accredited via ZKRD.

This operational user guide may be amended by DKMS from time to time to take account of changes in medical practice, in operational or administrative procedures. DKMS will announce any change to this operational user guide on the DKMS Professionals’ Platform (https://professional.dkms.org/) 30 days before coming into effect.

2 Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADCU</td>
<td>Adult Donor Cryopreserved Unit</td>
</tr>
<tr>
<td>BM</td>
<td>Bone Marrow</td>
</tr>
<tr>
<td>CBU</td>
<td>Cord Blood Unit</td>
</tr>
<tr>
<td>CCR5</td>
<td>C-C Chemokine Receptor type 5</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CT</td>
<td>Confirmatory Typing (donor request)</td>
</tr>
<tr>
<td>CVC</td>
<td>Central Venous Catheter</td>
</tr>
<tr>
<td>DLI</td>
<td>Donor Lymphocyte Infusion</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic Acid</td>
</tr>
<tr>
<td>EMDIS</td>
<td>European Marrow Donor Information System</td>
</tr>
<tr>
<td>GRID</td>
<td>Global Registration Identifier for Donors</td>
</tr>
<tr>
<td>HLA</td>
<td>Human Leukocyte Antigen</td>
</tr>
<tr>
<td>HAC</td>
<td>Health and Availability Check</td>
</tr>
<tr>
<td>HHQ</td>
<td>Health History Questionnaire</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HSC</td>
<td>Hematopoietic Stem Cell</td>
</tr>
<tr>
<td>HSCT</td>
<td>Hematopoietic Stem Cell Transplantation</td>
</tr>
<tr>
<td>IDM</td>
<td>Infectious Disease Marker</td>
</tr>
<tr>
<td>MM</td>
<td>Mismatch</td>
</tr>
</tbody>
</table>
3 Quality Standards for Transplant Centers

3.1 Transplant Center Evaluation according to WMDA Criteria

Transplant centers cooperating directly, i.e. not via a national registry, with DKMS Registry are evaluated according to the WMDA transplant center evaluation criteria before any donor can be requested. The transplant centers are asked to provide specific details which are reviewed and eventually approved by the DKMS Review Board. In case two reviewers come to different conclusions about the acceptability of the transplant center, the case is reviewed and decided by the Chief Medical Director of the DKMS Group. A reassessment of the evaluation takes place every three years.

4 Donor Search Process and Requirements

4.1 Transplant Indication (Diagnosis)

DKMS is responsible for donor safety and must thus ensure that stem cell products are only provided to patients for whom an unrelated hematopoietic stem cell transplantation (HSCT) is an acceptable medical treatment. Each patient for whom a DKMS donor is being considered as a potential unrelated donor must satisfy DKMS Registry’s requirements regarding diagnosis. Diagnoses that are standard indications for HSCT do not need to fulfill further requirements. The classification

If the indication for which the transplant center or registry is requesting a donor is not a standard indication for HSCT, DKMS Registry will consult its medical advisor and ask for an assessment of the case. In order to get a decision by the advisor, DKMS Registry may request further clinical information, e.g. an ethics committee vote, the study protocol or relevant case studies, from the transplant center or registry.

4.2 Patient Age

Each patient for whom a DKMS donor is requested for workup, must satisfy DKMS Registry’s requirements regarding age. If the age of the patient for whom the transplant center or registry is requesting a donor is above 80 years, DKMS Registry will consult a medical advisor and ask for an assessment of the case. In order to get a decision by the advisor, DKMS Registry may request further clinical information from the transplant center or registry.

4.3 Limit of Mismatch Level

DKMS expects that requested donors have a 10/10, 9/10 or 8/10 match grade unless the patient is part of a study with specific criteria for mismatched donor selection. If the match grade between patient and donor is less than 8/10 and the patient is not participating in a mismatch study, DKMS performs a global donor search upon receipt of a workup request to ensure that no better matching donor has been overlooked. If there is a donor with a higher match grade for the patient, DKMS will inform the transplant center or patient registry about this donor.

Matching lists for donors with ≤8/10 matching are only provided upon request via email and may not be received via EMDIS or other systems. Individual ≤8/10 donors can be sent as search results via EMDIS upon request, so that donor request can be started via the system.

4.4 Required Information about the Patient

To search for unrelated donors at DKMS Registry, a donor search has to be initiated by sending relevant patient information. While a preliminary search request only provides match list results on potential stem cell donors, an active search must be started to perform donor requests (e.g. Confirmatory Typing).
1. Patient HLA typing

- **Requirements for preliminary search:**
  Minimum: HLA-A, -B, -C, -DRB1 low resolution DNA-based typing. Recommended: High resolution HLA typing is highly recommended for HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 before starting an unrelated donor search. This level of typing accelerates the search process. Low resolution HLA typing decelerates the search procedure by initially only identifying potentially matched donors.

- **Requirements for search activation (needed to start requests):**
  Minimum: HLA-A, -B, -C, -DRB1 high resolution DNA-based typing. Recommended: High resolution typing for HLA-A, -B, -C, -DRB1, -DQB1, -DPB1. Additional parameters (e.g. CMV status, blood group, ...) can further enhance donor selection.

"A high-resolution typing result is defined as a set of alleles that encode the same protein sequence for the region of the HLA molecule called the antigen binding site [...]" (Nunes E *et al.* (2011), ‘Definitions of histocompatibility typing terms’ In: Blood, 118 (23): e180–e183).

The antigen binding site is encoded by exon 2-3 for class I and by exon 2 for class II HLA alleles.

Before requesting a workup at DKMS, verification of patient HLA typing results from an independent sample is recommended. It is the obligation of the transplant center to ensure that HLA verification typing of the patient is performed at the latest before the donor starts mobilization or the collection procedure or before patient starts conditioning, whichever comes earlier.

2. Medical and personal data for donor search and donor request initiation

The following information of the patient must be provided by the transplant center or patient registry at the preliminary and active search stage:

- Patient ID
- Patient’s name
- Patient’s sex
- Patient’s date of birth
- Patient’s diagnosis

The following additional information must be provided by the transplant center or patient registry at the time of a pre-workup request for a specific donor:

- GRID of the requested donor

Specific information required for a workup request is further defined in the workup section below (chapter 6).
4.5 Matching Algorithm

1. Algorithm
DKMS Registry’s search algorithm Hap-E Search® uses a probabilistic donor-recipient matching algorithm based on haplotype frequencies:

2. Ranking of matching list
- 10/10 matching list:
  - 10/10 matching probability
  - Younger donor before older donor
  - Male before female
- 9/10 matching list:
  - 9/10 matching probability
  - 8/10 matching probability
  - Mismatch loci: HLA-DQB1 mismatch before HLA-A, -B, -C or -DRB1 mismatch
  - HLA-C* 03:03 vs C*03:04 mismatch before other mismatches at HLA-A, -B, -C or -DRB1
  - Younger donor before older donor
  - Male before female

4.6 (Preliminary) Donor Search by International Registries

All searches, preliminary and active, are free of charge. Searches for donors from DKMS DE, PL, UK, CL, DKMS BMST IN and DKMS Africa at DKMS Registry can be initiated in three different ways:

1. Via the European Marrow Donor Information System (EMDIS)
DKMS Registry (hub code = DR) is connected to several registries via EMDIS. Donor search requests as well as typing requests (TYP_REQ), sample requests for Confirmatory Typing (SMP_REQ), infectious disease marker request (IDM_REQ) and donor reservation requests (RSV_REQ) can be received via EMDIS. See also our EMDIS National Rules available at WMDA or via our website (https://professional.dkms.org/services/dkms-services/dkms-registry-services/emdis-connection-to-dkms-registry) for further information.

2. Via E-Mail/Fax using WMDA forms
DKMS Registry also accepts requests by fax (Fax No. +49 7071 943 2299) or email (services@dkmsregistry.org) for all services. For requests by fax or email, we
recommend the use of WMDA forms (https://wmda.info/professionals/optimising-search-match-connect/wmda-forms), but we also accept other forms as long as they contain the information needed to perform the requested task (see chapters 1, 4, 5, 6.)

DKMS Registry will send a search report, consisting of DKMS donor (DE, PL, UK, IN, CL, ZA) matching results, usually within one business day after receipt of the search request.

DKMS updates its donor data on WMDA Search & Match Service every day, so that registries and transplant centers using this service have up-to-date information. Further, with the implementation of Match-Connect, the formal search at individual registries becomes a redundant step. Thus, it is acceptable to send the patient information directly with the first donor request and to skip the formal step of (preliminary) search. DKMS Registry will still run the search but not provide results by e-mail / fax if this step is requested to be skipped (other channels like Donor Navigator / EMDIS will still deliver search results).

3. Via Donor Navigator® Software

International registries and transplant centers that are registered users of DKMS Registry’s web application Donor Navigator® can and are encouraged to initiate their donor searches and all subsequent requests for DKMS donors through Donor Navigator® in case no EMDIS connection is available.

- The registration is free of charge and includes an online introduction to Donor Navigator® and its features. Access to Donor Navigator® requires a two-factor authentication provided by DKMS Registry.
- The additional benefits for registered Donor Navigator® users comprise an overview of all cases of their registry, search unit or transplant center, access to the updated progress tracking of each request and a user-specific notification system via email and within the software. Also, the system allows digital workup requests. Existing data such as contact information, patient as well as donor information is automatically populated in the forms.

4.7 Cancellation / End of Donor Searches

DKMS Registry expects the requesting registry to stop donor searches with DKMS Registry in case a donor is no longer needed for the patient. Reason for status change should be provided via EMDIS or other communication according to the EMDIS semantics (https://share.wmda.info/x/BYC7BQ) and as defined in the WMDA data dictionary (https://datadictionary.wmda.info/emdis/field/392/index.html). DKMS Registry reserves the right to deactivate a donor search after a reasonable time of inactivity. Deactivating in this context means that we will stop providing daily donor updates for this search.
5 Pre-Workup Requests

5.1 Typing Request

Most DKMS donors are typed in HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 in high resolution, allowing easy identification of 10/10 matches. In case donors do not fulfill these requirements or if additional information is needed before confirmatory typing to identify the best matching donor, extended typing can be requested.

The range of results being requested varies between the whole set of HLA genes (HLA-A, -B, -C, -E, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, -DPB1), as well as KIR, CCR5 and MICA/B. It is also possible to request only single genes, e.g. in search of a permissive/non-permissive mismatch of HLA-DPB1, a request only for HLA-DPB1 is possible.

Included in a typing request is:

- Donor availability check
- Health History Questionnaire (HHQ) and first assessment of donor suitability. The transplant center will be notified about medical details if relevant.
- DNA-based typing from stored samples or fresh sample (blood or buccal swab) in the EFI accredited DKMS Life Science Lab.

5.2 Infectious Disease Markers Testing (IDM Testing)

In case of a pre-selection of multiple potentially matching donors, it might be helpful to know the infectious disease markers or the CMV status to determine the best matching donor(s). IDM requests can be filed in parallel to a typing request, but can also be requested separately. Besides our standard set of IDMs, it is also possible to request individual markers separately.

Included in an IDM testing request is:

- Donor availability check
- Health History Questionnaire (HHQ) and first assessment of donor suitability. The transplant center will be notified of medical details if relevant.
- Donor blood sample for IDM testing and shipment to DKMS partner lab.
- IDM testing profile: IDM testing includes testing for diseases thought to be important to consider in hematopoietic stem cell transplantation, the minimum set aligns with WMDA Standards. The detailed composition of markers to be tested differs according to the country of origin of the DKMS donor. A list of standard markers per DKMS entity included in the respective request can be found in our Specification of Services.
An example of our Specification of Services is available on our website. The current Specification of Services valid for your country can be requested at services@dkmsregistry.org.

5.3 Health and Availability Check (HAC)

As most DKMS donors are typed at high resolution for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 by NGS, the error rate is very low (see Baier, D.M., Hofmann, J.A., Fischer, H. et al. Very low error rates of NGS-based HLA typing at stem cell donor recruitment question the need for a standard confirmatory typing step before donor workup. Bone Marrow Transplant 54, 928–930 (2019)). Therefore, identification of a fully matched donor is often possible at the start of a search. Further, some of our donors already have confirmed typing results from previous requests. However, the availability of the donor and medical information might not be up-to-date. DKMS offers transplant centers the possibility to request a HAC instead of CT, in order to speed up donor screening and proceed faster to workup as HLA verification typing is only performed on the donor selected for workup. The typing will then be performed during workup from blood collected with the pre-collection samples, taken from the donor on the day of physical examination. High resolution HLA verification typing results must be reported to DKMS prior to the patient starting conditioning, or the donor receiving G-CSF or being admitted for bone marrow harvest, whichever happens first.

The following criteria need to be fulfilled to request a HAC:

- DNA-based high resolution typing for at least HLA-A, -B, -C, -DRB1 and -DQB1 must be available for this donor. Otherwise, a HAC is only possible in case of confirmed urgency e.g. based on the specific diagnosis and the desired time frame for transplantation (< 6 weeks to transplantation).

Included in a HAC request is:

- Detailed information session with the donor by phone and availability check.
- Health History Questionnaire (HHQ) and assessment of donor suitability. The transplant center will be notified of medical details if relevant.
- Donors will be reserved directly after receipt of the HAC request. Reservation will initially be set for six weeks.
- After a successful completion of a HAC request, the donor is reserved for three months.

Important note: A HAC can be performed instead of, but not in advance of, a CT request. It is not allowed that the transplant center request a CT shortly after a completed HAC. The information session and Health History Questionnaire included in a HAC are the same as performed during a CT request. If the transplant center requires the donor’s IDM testing results for donor selection, a CT must be requested directly as the initial request.
5.4 Confirmatory Typing Request (CT)

HLA verification typing of donor and recipient is always required before a recipient can receive a stem cell product from an unrelated DKMS donor and must be performed either before or during workup. HLA verification typing must be performed from a fresh sample of the potential donor.

When Confirmatory Typing is requested and processed before workup, it includes the following elements:

- Detailed information session with the donor by phone and availability check.
- Health History Questionnaire and assessment of donor suitability. The transplant center will be notified of medical details if relevant.
- IDM testing according to standard profile described in our Specifications of Services.
- Donor blood sample for HLA verification typing.
- Shipping of samples to the lab designated by the requesting transplant center.
- Donors will be reserved directly after receipt of the confirmatory typing request. Reservation will initially be set for six weeks.
- Once contact has been made with the donor, the reservation will be extended to 3 months after the estimated blood draw date.

The maximum amount of blood to be drawn at CT must not exceed 50 ml.

An example of our Specification of Services is available on our website [https://professional.dkms.org](https://professional.dkms.org). The current Specification of Services valid for your country can be requested at services@dkmsregistry.org.

5.5 Repeated CMV Testing at Pre-Workup Level

To protect donors from unnecessary multiple blood draws, DKMS can only offer to repeat CMV testing on CT level if the initial result is inconclusive. If either CMV IgM or CMV IgG is ‘indeterminate’ and all other CMV parameters are negative, a second blood draw and CMV antibody screening 4 weeks after the first one can be requested via DKMS Registry or other respective registries in charge. CMV PCR testing can be included if an immediate Workup request is pending.

In any other constellation including CMV IgM positivity - isolated or in combination with persisting CMV IgG -, re-testing will be performed only at WU stage. At CT health assessment, our donors are asked about symptomatic infections, and would be blocked accordingly if they report relevant findings.
5.6 Research Studies at CT Level

Research studies to support donor selection may be important for the transplant outcome of the patient. DKMS generally supports studies if they can result in a benefit for patient care or increase safety of donors and the additional burden on the donor is acceptable.

- All studies have to be approved by DKMS.
- DKMS allows only one study per case.
- For any research studies, transplant centers have to provide the full study synopsis, approval of the ethical review board, as well as translated information and consent form for donors (English or language of involved DKMS donor center).
- Any genetic testing must be approved by DKMS and thus specified in the study synopsis.
- Without approval for the study request, the transplant centers are not allowed to perform any tests with donor material (blood) which exceed the regular tests for donor selection.

5.7 CCR5 Verification at CT

About 1% of the Northern European population carries the Δ32 mutation of the CCR5 gene homozygously. Homozygous carriers of this mutation are resistant to M-tropic strains of HIV-1. Therefore, CCR5 testing can be performed for patients with a hematological disease who are also HIV-1 positive. DKMS has performed CCR5 tests for all donors at donor recruitment since 2014.

- In cases when CCR5 is relevant for donor selection, CCR5 testing has to be confirmed before donation, e.g., at the Confirmatory Typing step. DKMS can provide access to laboratories that can perform CCR5 testing.

5.8 Donor Reservation

- Without any previous request, a reservation of one of our donors is not possible.
- Donors are currently not reserved after completed Typing Request or IDM Testing. However, an adjustment is planned for 2024 so that the donors are also reserved during and after these request types.
- Donors are reserved for three months after a CT request or after a completed HAC.
- When the reservation after a CT request or HAC has expired, an extension of reservation for an additional three months is possible without reason.
- After six months reservation period, a justification is required if a further extension of three months is desired.
- After the nine months reservation period, we expect the workup request to be sent.
- In exceptional cases, a new HAC request can be placed to extend the donor’s reservation period one more time. A new reservation without a new request is not
possible, because the information about the availability and the medical suitability of the donor should be verified again after 9 months at the latest.

6 Workup (HSC Apheresis, HSC Bone Marrow, MNC Apheresis)

6.1 Workup Process

DKMS Registry will confirm receipt of each workup request by automated email notification.

After the workup request form is received by the DKMS donor center, it is checked for completeness and correctness. The following information must be provided by the transplant center at the time of a formal request for a stem cell donation:

- Patient ID
- Patient HLA typing results: Minimum HLA-A, -B, -C, -DRB1 high resolution DNA-based typing
- Patient's name
- Patient's sex
- Patient's date of birth
- Patient's diagnosis
- Patient's weight
- Patient's blood group and rhesus factor
- Transplant center name
- Email address and name of contact person at transplant center and/or patient registry
- GRID of the requested donor
- Product preference
- Preferred (first) collection date
- Infusion date
- Required date of clearance
- Duration of the conditioning
- Information if other donors are being considered for donation for this patient.
- Indication of whether the donor is the primary or backup donor.
- Pre-collection samples requirement
- (Pre-collection samples shipping address)
- Prescription for HSC collection, detailing desired cell dose, additives, and anticoagulants
- Collection day samples requirement
- Transport temperature
- Shipping address (if different from transplant center's address)
• HLA verification typing results (DNA-based typing results for HLA-A, -B, -C, -DRB1 and -DQB1) from the requested donor.

If the workup request form contains all necessary information, it is assigned to a case manager. After the workup request has been assigned to a DKMS case manager, the transplant center or patient registry is informed of the case manager’s name and contact information. The case manager will then contact the donor as soon as possible to discuss all details and coordinate the collection.

The following details will be discussed with the donors during the workup procedure:
• Different methods of blood stem cell donation and the transplant center’s preferred stem cell product type
• Information about the risks and side effects of the donation
• Willingness of the donor to proceed with the donation
• Availability of the donor for the requested dates and donation method as well as time commitment
• Time frame of medical examination and donation
• Location of the collection center
• The physical examination procedure incl. the requirement of further tests and blood samples before donation
• Anonymity of the donor and patient and confidentiality of personal data
• Whether the donation is part of a clinical trial for the patient
• The donor’s right to withdraw consent and consequences of withdrawal after patient conditioning has begun
• Possibility of request for subsequent donation of hematopoietic stem cells or blood products
• Reimbursement and provision of expenses
• Insurance coverage

6.2 Maximum Number of Donations for DKMS Donors

<table>
<thead>
<tr>
<th>Glossary</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsequent Donation of HSC</td>
<td>After the completion of an HSC collection, the same donor is requested for the same patient again: HSC Apheresis or HSC Bone Marrow</td>
</tr>
<tr>
<td>Subsequent Donation of Blood Products</td>
<td>After the completion of an HSC collection, the same donor is requested for the same patient again: MNC Apheresis or requests for additional blood samples for further testing (e.g. virus-specific T-Cells)</td>
</tr>
<tr>
<td>Multi-Donation</td>
<td>The respective donor completes more than one HSC collection for different patients.</td>
</tr>
<tr>
<td>Second Transplant</td>
<td>The respective patient receives a second HSC product from a donor different from the previous donor.</td>
</tr>
</tbody>
</table>
Subsequent Transplant

| The respective patient receives a second HSC product from the same donor. |

If patients have a relapse or a graft failure, a subsequent donation of HSC from the same donor can become necessary. This happens in approximately 2-3% of our cases. A donor can also be requested as best match for a different recipient (<1% of cases). To protect donors, the number of donations for HSC Apheresis or HSC Bone Marrow is limited to two collections per donor for each product type. There is no defined maximum number of donations for MNC Apheresis. However, when the donor is requested for MNC Apheresis the third time, a medical advisor will be contacted to evaluate the indication.

Subsequent Donation:
- The transplant center must provide a written reason to justify the need for a subsequent donation and the WMDA F20 form (Previous Transplant History) or equivalent
- Subsequent donations of HSC for the same patient have to be approved by the medical advisor of DKMS. DKMS will aim to provide a decision within 72 hours of receipt of the subsequent donation request. Pending the medical advisor's decision, the donor will not yet be contacted.
- After a completed workup, only a subsequent workup or MNC Apheresis request is accepted for the same patient. HAC requests are not accepted in between.

Multi-Donation:
- Transplant centers will already be informed at the time of pre-workup request, if a donor has donated before, as the donor will only be available for the same stem cell product type one more time.

6.3 Interval between Donations

After an HSC donation the donor may suffer from side effects for some time. Therefore, there is a defined minimal interval between two donations.

- The interval between two PBSC donations should be at least 4 weeks as a graft failure cannot be diagnosed earlier.
- In urgent cases, e.g. poor mobilization, it might be possible to shorten the interval between donations, and switching the cell source (PBSC to BM / BM to PBSC) if not contraindicated.
- The interval between two BM donations should be at least 4 weeks. It will be reassessed and approved by the medical officer for each individual case. A PBSC donation should be considered for the second request, if possible.
- There is no defined minimal interval for MNC Apheresis. However, the donor blood count must be in normal range.
• A subsequent donation can only occur if the donor has fully recovered. All decisions have to be made after individual consideration.

• DKMS BMST Foundation India only provides PBSC products. DKMS BMST donors in India are not allowed to undergo any type of second donation (including MNC Apheresis) within 6 months after a peripheral stem cell harvest due to Indian law. Consequently, we recommend to request a higher cell count for the first donation, if possible, and to cryopreserve a part of the product for a potential subsequent transplant.

6.4 Cell Count Requests

We observe a huge range in requested CD34⁺ cell counts for HSC Apheresis from $1.5 \times 10^6$ CD34⁺/ kg to $50 \times 10^6$ CD34⁺/ kg body weight of the recipient. Generally, a CD34⁺ cell count of $5 \times 10^6$ CD34⁺/ kg recipient body weight is considered sufficient. However, there are protocols in use that require higher numbers of CD34⁺ cells. For HSC Bone Marrow, the requested TNC usually is within a range of $3-5 \times 10^8$ TNC/ kg body weight of the recipient. For children with rare diseases (e.g., SCID, other congenital disorders or metabolic diseases) as well as for patients with SAA, a higher cell count may be reasonable, as there is a higher possibility of graft failure.

• For HSC Apheresis, the transplant center must justify requests for CD34⁺ cell counts exceeding $5 \times 10^6$ CD34⁺/ kg recipient body weight. Requests exceeding $5 \times 10^6$ CD34⁺/ kg recipient body weight without a plausible explanation cannot be accepted.

• For HSC Bone Marrow the collection of TNC is limited, as only 20 ml bone marrow / kg body weight of the donor may be collected. Usually, a maximum volume of about 1,500 ml is collected.

• Transplant centers should thus consider donor’s weight when requesting a BM product.

• If the HSC product is being cryopreserved, a higher number of cells might be approved provided that it is still feasible for the donor.

6.5 Simultaneous Confirmatory Typing and Workup

As nowadays HLA results from donor registry typing are very accurate, a transplant center can very often identify a match for a patient immediately on the search results list. Therefore, in urgent cases or in cases where the donor was already requested multiple times for CT for different patients, the HLA verification typing can be shifted to the workup process. In these cases, it is possible to request CT and workup at the same time. The transplant center has to consider that CT unavailability varies depending on the DKMS entity. For this reason, it is recommended that a Health and Availability Check (HAC) has been completed before a simultaneous CT and workup is requested to verify the donor’s availability and medically suitability. A HAC does not include IDM testing which will be performed only during workup in these cases.
• DKMS accepts workup requests without preceding CT request. The blood draw for HLA verification typing takes place at the time of physical examination. High resolution HLA verification typing results must be reported to DKMS prior to the patient starting conditioning, or the donor receiving G-CSF or being admitted for bone marrow harvest, whichever happens first. Please consider: Transport of blood samples to the HLA typing lab and time to receive HLA typing results need to be calculated in the time between WU request and collection. If the transport time or the laboratories turn-around time is longer than few days, either CT before workup or HLA typing at faster labs should be considered to not delay the WU procedure.
• Note: If the transplant center requires that the blood samples for HLA verification typing are drawn before physical examination, CT and workup must be requested separately.

6.6 Postponement of Workup

If the donation date has to be rescheduled, DKMS will ensure that repeat infectious disease markers testing is performed if the last testing was performed on blood samples taken more than 30 days prior to the new donation date. Between 84 and 184 days since the last complete physical examination, additionally blood tests including a complete blood count will be repeated. If the donation date has been postponed by more than 184 days, DKMS will arrange a repeat of a full physical examination of the donor including repeat infectious disease markers testing.

6.7 Number of Donors Requested for one Patient at the same Time

At DKMS, the workup unavailability rate is approximately 15 % globally, including temporary reasons.

• DKMS accepts that a transplant center requests more than one donor for WU. However, the requesting transplant center / registry must inform DKMS if a donor in such a case is the primary or backup donor. This also applies if one of these donors is not a DKMS donor but a donor from another donor registry.
• The primary donor will be contacted as usual and will not be informed that there is another donor requested for workup.
• If the DKMS donor is the backup donor, he/she will be contacted and informed that he/she is a backup donor and therefore might not be requested to donate, if the primary donor is able to proceed in the requested time frame. The information session will be performed with the backup donor to assess willingness and availability but no collection slots will be blocked in the collection center facilities.
If there is an increased risk that the primary donor will be unavailable, DKMS may, in exceptional cases, plan collection dates with both donors simultaneously. Further exceptions can be made in individual cases, e.g. if several donors have already failed for a patient and the urgency is given.

6.8 Replacement Donor Search at Workup

With a global DKMS donor pool of more than 11 million donors, many patients have more than one potential DKMS donor. In case a donor becomes unavailable for the patient during workup, DKMS starts a replacement donor search within all DKMS donors.

- As soon as we learn that a donor might be unavailable for the patient (e.g. donor is unavailable for the requested period or the stem cell source the transplant center is requesting), a replacement donor search is started.
- Transplant centers are informed about the outcome of the replacement donor search.
- In addition to the manually triggered replacement donor search, an automated replacement donor search is running at the start of each workup. If there are no other matching donors available, DKMS types potentially matching donors who are not fully typed at own costs.

6.9 Research Studies at Workup Level

Research studies for better treatment or outcome of the patients are important. DKMS therefore supports studies if they can result in a benefit for patient care or increase the safety of donors if the additional burden on the donor is acceptable.

- All study requests have to be approved by DKMS.
- DKMS allows only one study per case.
- The study request has to be sent to DKMS with the workup request.
- Study requests received after physical examination of the donor cannot be accepted.
- For any research studies, transplant centers have to provide the full study synopsis, approval of the ethical review board, as well as translated information and consent form for donors (English or language of involved DKMS donor center).
- Any genetic testing must be approved by DKMS and thus specified in the study synopsis.
- Without approval for the study request, the transplant centers are not allowed to perform any tests with donor material (blood, BM, PBSC, MNC products or data) which are not standard requirement for either donor selection or transplantation.
6.10 Research Study after donation OR Donor Blood Samples after Donation

- If additional donor blood samples are required after donation, they can be requested via e-mail request to workup@dkmsregistry.org.
- If the transplant center wants to use stored donor samples after stem cell infusion for research study or alternative use, a new donor consent form must be gained to use these samples. Request for donor consent must be sent to workup@dkmsregistry.org.
- The use of stored donor samples for quality control or testing related to the treatment protocol of the patient, does not require additional consent of the donor.

6.11 Cryopreservation of Stem Cell Products

Stem cell products from unrelated donors are normally transplanted fresh, once the product has arrived in the transplant center and the quality assessment at the transplant center has been performed. Under certain circumstances, a cryopreservation of the product can become necessary.

- DKMS has to approve any cryopreservation request. To be able to approve the request, DKMS needs a detailed justification for the cryopreservation request.
- Due to many unused products, DKMS approves cryopreservation only if there is already a clear schedule for transplantation. **If the patient condition changes, a postponement of the collection date is generally preferred even in case cryopreservation was accepted.**
- Cryopreservation of bone marrow products is associated with higher cell losses. DKMS will approve such requests only when high TNC counts are expected with regard to the weight ratio between patient and donor.
- Transplant centers must indicate the minimum cell counts required upon arrival at the transplant center. If the requested cell count is not feasible according to the donor center’ or collection center’s estimation, cryopreservation cannot be approved.
- The donor is contacted by the workup case manager and informed about the cryopreservation request. The donor has to agree to the cryopreservation of his/her product and give consent before cryopreservation can be finally approved.
- A clear timeline for the start of conditioning and the date of transplantation must be communicated before cryopreservation can be approved.
- Infusion should be scheduled as soon as possible and pre-transplant conditioning should start immediately after safe arrival of the product or, in case of recipient-related cryopreservation, once health status is appropriate.
- If the required information about the planned cryopreservation has not been provided before the start of the mobilization, the collection center, donor center or the donor may not proceed with the donation.
- DKMS will follow-up with the transplant center as long as the cells are cryopreserved and not infused. The transplant center needs to inform DKMS when they have infused the cells. If the cryopreserved product will not be used for the intended
patient, the transplant center must also inform DKMS and explain why the product cannot be used.

- If the cells will definitely not be infused, some DKMS entities may ask transplant centers to keep unused PBSC products cryopreserved for the time being and / or initiate retrieval of those cells to be stored at DKMS Stem Cell Bank.
- As unrelated stem cell products are directed to a single patient, it is not allowed to use cells for another purpose, e.g. science, studies or validation processes without approval from DKMS and a specific donor consent.
- DKMS has to give final approval before cells are destroyed. Under no circumstances the cells should be destroyed while the patient is alive.
- Donors will always be kept updated about the infusion or non-infusion of their stem cells.

6.12 Partial Cryopreservation of Excess Cells of Stem Cell Products

If the stem cell product contains more cells than needed, the transplant center should cryopreserve residues of the HSCs or MNCs for a later use.

- Donors agree on the consent form, that portions of the stem cell product can be cryopreserved if the stem cell product contains more cells than needed. Excess cells can only be used as a subsequent transplant for the same patient.
- If remains of the stem cell product are no longer needed for the patient, the transplant center must discard the cells. A specific information to DKMS is not required.
- It is not allowed to use the product for research or any other purposes without approval of DKMS and explicit consent by the donor.

6.13 Cryopreservation of MNCs

Donor MNC products usually are portioned and most parts are cryopreserved. One portion should be infused freshly.

- A transplant center needs to inform DKMS if they plan to cryopreserve the complete product and not infuse at least one fresh portion within 14 days. A reason and the plan for infusion should be communicated so that the donor can be informed correctly.
- If the transplant center wants to cryopreserve the lymphocytes for longer than 14 days before administering the first dose, the cryopreservation of MNC products is also subject to approval by DKMS and the donor.
- If an infusion seems very unlikely, the transplant center should consider postponing the MNC Apheresis.
• DKMS will follow-up with the transplant center some days after the planned date of the first infusion and inform the donor accordingly. Any changes of plans or delays should be communicated by the transplant center actively and in a timely manner.

6.14 Unavailability of a Donor for One Product Type

DKMS donors registered with the DKMS Donor Center gGmbH in Germany (DKMS DE), Fundacja DKMS in Poland (DKMS PL), DKMS Foundation in the United Kingdom (DKMS UK), Fundación de Beneficencia Pública DKMS in Chile (DKMS CL) and DKMS in the USA (DKMS USA) are generally available for both product types, unless otherwise specified during the donor request following medical assessment. DKMS donors registered with DKMS BMST Foundation India (DKMS BMST IN) and DKMS Foundation NPC in South Africa (DKMS Africa) are only available for HSC Apheresis.

For recipient safety, transplant centers can request approval for cryopreservation of the stem cell product if a donor is only available for one stem cell source (HSC Apheresis or HSC Bone Marrow).

• HSC Apheresis: If the donor is only available for HSC Apheresis, the transplant center can request approval to cryopreserve the stem cell product in case the donor turns out to be a poor mobilizer and no sufficient cell count can be collected. If the donor does not give his/her consent to a cryopreservation, the transplant center will be informed accordingly.
• HSC Bone Marrow: If the donor is only available for HSC Bone Marrow, cryopreservation of the product can also be approved. However, the expected cell counts have to meet the minimum requirement of TNC cells by the transplant center and transplant center must have expertise in cryopreservation of BM products.
• Even in these cases, the transplant center must request approval for cryopreservation from DKMS. A scheduled transplantation date is a prerequisite for approval.

DKMS recommends to infuse cells fresh wherever possible and to have a backup plan for each transplantation (e.g. other donor or therapeutic cell source).

6.15 Additional Testing Requests by the Transplant Center

In some countries, transplant centers have to perform additional tests, which are not relevant for donor clearance in the donor’s country.

• Transplant centers have to inform DKMS of any additionally required tests in good time before the donor’s physical examination. DKMS checks if it is possible to perform the tests in the laboratory of the collection center and informs the transplant center about the additional cost.
• The transplant center then decides if they want to perform the additional test themselves out of the pre-collection samples or if they want DKMS to perform the test and agree to pay the additional cost.
• If DKMS performs the test, results are communicated together with the donor final clearance.

6.16 Maximum Amount of Blood to be drawn at Physical Examination (Pre-Collection Samples)

Pre-collection samples of donors are often requested as part of the workup request. Transplant centers can perform specific tests required before transplantation.

- Pre-collection samples are drawn at the time of physical examination (PE).
- The maximum amount of blood for pre-collection samples to be drawn at PE is 50 ml.
- Exceptions can be taken into consideration on a case-by-case basis.
- For NMDP requests, 35 ml cannot be exceeded as additional blood tubes have to be drawn for FDA-approved infectious disease marker testing.

6.17 Transplant Center Acceptance of Formally Ineligible Donors

If the physical examination reveals that donation bears no increased risk for the donor but the potential transmission of a condition or disease to the recipient as specified in the respective official guidelines of the donor’s country, such a donor may only be cleared after written acceptance by the transplant center. Examples: travel history, sexual high-risk behavior, enzyme deficiency (G6PDH).

6.18 Donor Reservation after Donation

All DKMS donors are reserved for the patient for whom they have donated for a period of two years (starting from the first day of collection). Transplant centers can ask for a prolonged reservation in case they may consider a subsequent donation from the same donor in the near future. DKMS informs the transplant center within 5 years after the first transplantation if the donor will be no longer available for subsequent donations.
7 Requests for Adult Donor Cryopreserved Units (ADCU)

DKMS Stem Cell Bank provides so called adult donor cryopreserved units that originate from a peripheral stem cell collection of a donor. Specifically, when a donor is requested for PBSC for a specific patient, donors with frequent HLA types and specific characteristics (such as age, donor/patient weight ratio, requested cell dose) may be considered for a prolonged apheresis to obtain an additional stem cell product. Specific informed consent will be requested from these donors with expected excessive mobilization of CD34+ cells. On the day of apheresis, the final decision will be made if sufficient CD34+ cells (plus margin) have been donated for the regular WU request and the requesting patient (directed product). Further surplus of cells will be cryopreserved at DKMS Stem Cell Bank as undirected stem cell product, i.e. available for any patient. The transplant center will be informed once an ADCU has successfully been manufactured.

The search result for an ADCU will show details such as CD34+ cells, volume, age of donor at day of donation, HLA profile, IDMs and date of collection. Specifications (unit report) of the ADCU can be requested at DKMS Registry in order to decide whether to request a matched ADCU. The ADCU can be requested either as primary or secondary transplant.

Procurement of an ADCU can be realized within 3-5 days. DKMS SCB will perform quality tests and verification typing prior to procurement. To request an ADCU, the DKMS request form "Formal request for ADCU" must be used and sent to DKMS Registry. The date of requested shipment and date of planned start of conditioning and transfusion must be given.

8 Transport

International registries and transplant centers usually arrange for the transportation of the stem cell product from the collection center to the appropriate transplant center themselves, using their own volunteer or commercial courier.

If required, a courier can be arranged by DKMS for an additional fee. For some customers, it is agreed that DKMS will organize the courier as standard option.
8.1 Transport Arrangements by International Registries and Transplant Centers

Once the date of collection is confirmed, the DKMS case manager sends a form to the respective registry or transplant center to fill in the required information.

For international transport arrangements, the applicable DKMS or WMDA forms must be submitted.

DKMS needs to be informed about the following information:
- Name of the courier
- Courier’s date of birth
- Passport number including expiration date
- 24/7 mobile phone number of the registry or transplant center
- Date and time of arrival at the location of the collection center including the name of the hotel and a travel plan containing all transport information

8.2 Transport Arrangements to be made by DKMS

DKMS can organize the stem cell courier on behalf of the transplant center. This service is charged in addition. In case the transplant center asks DKMS to provide a courier, DKMS contacts a courier company to arrange the transport of the HSC / MNC product. The courier company forwards all relevant information about the courier including a main and an alternative travel plan to DKMS. These courier details are sent to the respective registry or transplant center. They may provide DKMS with additional forms that need to be forwarded to the courier in charge.

9 Donor Follow-Up

9.1 Post-Donation Follow-Up

Donor follow-up will be initiated after the first injection of a mobilizing agent, the administration of anesthesia, or the beginning of apheresis (in case of MNC Apheresis takes place before an HSC Apheresis), independently of completion of the collection. The donor’s health must be assessed to monitor the recovery process, long-term health effects after the donation and the availability for further donations.

- All DKMS donors have a minimum of 10-year post-donation follow-up.
- Follow-up questionnaires are sent out to the donor 1 month, 6 months, 1 year, and then annually until 10 years post-donation.
- For non-US donors a blood test is done 1 month post-donation.
• If there are abnormal findings, timely controls will be arranged with the donor upon the physician’s / medical advisor’s decision.

9.2 Adverse Events and Reactions Reporting (SEAR/SPEAR)

To ensure donor’s and recipient’s health and safety, all adverse events and reactions of unrelated donors or patients have to be reported to WMDA to gain insight in the occurrence of health incidents or risks. This also applies to MNC Apheresis.

SEAR Reporting

• The DKMS donor center affected by the SEAR submits the report to the registry it is associated with or directly to WMDA and to national authorities accordingly if required.
• At the end of the year a negative report is sent to WMDA in case there was no adverse event.
• If there is a risk of disease transmission to the recipient (e.g. infectious disease, malignancy), the transplant center will be informed.
• Any SEAR is documented in a way that allows tracking and analysis.

SPEAR Reporting

• Reporting product or patient adverse events / reactions is primarily within the responsibility of the transplant center and the associated patient registry.

10 Donor-Patient Contacts

10.1 Anonymity Criteria for DKMS Donors and / or Patients of DKMS Registry

Donor and recipient information are confidential for at least two years post-donation (1 year for US donors). If cells were cryopreserved the day of transplantation is relevant for the anonymity period. The goal of maintaining donor and recipient anonymity is to ensure privacy for both, donor and recipient. In some countries, no contact between donor and recipient is allowed. If regulations differ between donor and patient country, the stricter rule applies (e.g., if no contact between donor and patient is allowed in the donor or patient country, there will be no contact). If no laws of the donor or patient country conflict, the following applies:

• Anonymous correspondence between donor and recipient is allowed immediately after the transplantation, independently if the product was a PBSC, BM or ADCU.
• In case of DKMS donors, all correspondence is checked by DKMS employees to ensure confidentiality guidelines are met. The correspondence is documented in DKMS’ software.
• The exchange of photos showing people or recognizable locations / landscapes is generally not permitted. In particular, photos of donor, recipient or family members may not be exchanged.
• Post cards with indications of the donor’s or recipient’s residence are not allowed.
• Anonymous letters between relatives of deceased patients and their donors (or the patient and relatives of a deceased donor) are possible.
• One gift – meeting anonymity criteria – is allowed per side. The gift
  o should not be more expensive than 20 EUR / 20 USD.
  o should not contain anything fragile.
  o should not contain food items, including beverages or sweets.
  o should not contain audio files.
  o should not include gift certificates or money.

10.2 Patient Follow-Up Information

Stem cell donation is an altruistic act. Most donors are interested to know if the donation was successful and the patient has recovered after stem cell donation. In addition, engraftment data have to be obtained for the collection centers to prove their quality and fulfill requirements for JACIE accreditation.

• DKMS requests patient follow-up information usually three months after stem cell transplantation including engraftment data. The engraftment data will be sent to the respective collection center for their quality management and JACIE accreditation.
• Donors will be informed about the outcome of the patient’s transplantation but only basic and anonymous information is given to the donor.
• Upon a donor’s request, DKMS asks for further updates after 1 year and / or annually.
• After transfusion of an ADCU, the same processes of requesting patient follow-ups apply. However, due to regulatory requirements of DKMS SCB (pharmacovigilance), more frequent patient outcome data are required and forwarded to DKMS SCB.

10.3 Release of Personal Information between Donor and Recipient

If no laws of the donor or patient country conflict, two years after transplantation (for DKMS US donors 1 year), personal information of donor and recipient can be exchanged. If it is possible, the following applies:

• DKMS allows exchange of personal information between donor and recipient.
The release of personal information between donor and relatives of their deceased recipient (or vice versa) is also possible. The anonymity period of 2 years is lifted once the patient is deceased.

A subsequent donation or MNC Apheresis within the second year after transplant may prolong the confidentiality period. Another year of anonymity adds from the day of the second transplant date (for HSC donations) or three months from the day of infusion of the first portion of MNCs, respectively.

Either recipient (via the transplant center) or donor has to request the release of personal information.

Donor and recipient have to sign a consent form to release personal information.

The recipient’s written consent to release personal information to the donor should already be on file when the request is sent to DKMS.

Once DKMS has received the consent form from donor and recipient, the personal information can be exchanged.

After transfusion of an ADCU, direct contact between the donor and the patient may also be initiated after the anonymity period, following the same processes.

11 Finance

11.1 Fee Schedule

The current fee schedule of DKMS Registry can be requested at services@dkmsregistry.org. Any changes are communicated 30 days prior to becoming effective.

Each transplant center or registry is accountable for the payment of the fees according to DKMS Registry’s fee schedule. The accruing costs refer to the fee schedule that is valid at the time of request initiation. The invoice will be issued by the DKMS entity that performed the request, usually soon after service delivery. Payment term is 30 days.

12 Applicability for access via ZKRD, NMDP, Anthony Nolan and Poltransplant

This document describes rules and procedures for DKMS donors when mediated via DKMS Registry. Globally most rules apply also for other mediation channels. However, there might be national regulations that supersede DKMS guidelines. These are not specifically mentioned in this document but can be found in the individual national standards. Also, other contacts apply when searching and requesting DKMS donors via other registries.